Venous Thromboembolism

ORLANDO — The addition of aspirin to direct oral anticoagulant therapy for venous thromboembolism or nonvalvular atrial fibrillation appeared associated with increased rates of bleeding events compared with use of the anticoagulants alone, according to results of a registry-based cohort study presented at ASH Annual Meeting at Exposition.

Patients with inflammatory bowel disease, type 1 diabetes and venous thromboembolism have an increased risk for rheumatoid arthritis, which in turn increases the risk for cardiovascular disease, obstructive sleep apnea and — again — venous thromboembolism, according to data published in Mayo Clinic Proceedings.

During a recent webinar, ASH President Roy L. Silverstein, MD, highlighted three “potentially practice-changing” abstracts on venous thromboembolism that will be presented at the upcoming meeting in Orlando, Fla.

SAN ANTONIO — A post hoc analysis evaluating the safety of Xeljanz in ulcerative colitis revealed comparable incidence rates of pulmonary embolism and deep vein thrombosis in patients who did and did not receive the agent. However, researchers at the American College of Gastroenterology Annual Meeting stressed the need for more data to better understand the link between the agent and venous thromboembolic events after previous safety signals led to a change in prescribing guidelines in the United States.

Testosterone therapy is associated with an increased short-term risk for venous thromboembolism in all men, suggesting that physicians should use caution when prescribing the therapy, according to findings published in JAMA Internal Medicine.

Direct oral anticoagulants should be used to prevent venous thromboembolism among certain patients with cancer, as well as to treat those who develop blood clots, according to updated ASCO recommendations published in Journal of Clinical Oncology.

Higher estimated cardiorespiratory fitness levels appeared associated with a lower risk for venous thromboembolism, according to results of a population-based cohort study published in Journal of Thrombosis and Haemostasis.

Published results showed the noninferiority criterion of risk of venous thromboembolism or death was not met when low-intensity warfarin was compared with standard-intensity warfarin in patients who underwent total joint arthroplasty.

Warfarin and Pradaxa were both safe and effective at preventing recurrent venous thrombotic events in patients with cerebral venous thrombosis, according to findings from a randomized clinical trial published in JAMA Neurology.

Venous thromboembolism risk factors appeared highly prevalent among postpartum women at a Dublin hospital, according to results of a cross-sectional study published in Journal of Thrombosis and Haemostasis.